Infectious Units Assay

The assay counts particles that successfully initiate detectable infection in susceptible cells, rather than counting every physical particle present. Consequently, a sample can contain more total particles than infectious units if some particles cannot replicate or establish the measured infection. Reporting infectious units per volume therefore describes biological activity and is more informative for experiments that depend on productive infectivity.

Susceptible cell cultures provide the biological test system that converts infectivity into an observable signal. The chosen readout may be plaques, immunostained foci, or cytopathic effects, each representing detected infection in a different visual form. This cell-based step is essential because the result depends on whether the agent can produce a measurable infection in the cells used.

Serial dilution makes dense or otherwise uncountable infection patterns measurable across a range of sample concentrations. Counts from an appropriate dilution are then related back to the original sample volume to calculate infectious units per volume. Dilution choice, cell susceptibility, and the ability to detect the selected endpoint can therefore influence the reliability and interpretability of the result.

Plaques, immunostained foci, and cytopathic effects are alternative endpoints for detecting infection, not interchangeable descriptions of total particle abundance. Plaques and foci provide countable localized signals, whereas cytopathic effects rely on visible changes in infected cultures. Selecting among them depends on which infection-associated signal the system can reveal clearly, while keeping the biological interpretation tied to replication-competent agents.

A basic workflow starts by preparing serial dilutions of the sample, exposing susceptible cell cultures to those dilutions, and allowing infection to become detectable. The experimenter then records plaques, immunostained foci, or cytopathic effects at the relevant endpoint and uses the count with the dilution information to express infectivity per volume.

For stock characterization, the measurement indicates how much replication-competent infectious material a preparation contains, supporting comparison among samples. In antiviral evaluation, changes in infectious units can show whether treatment reduces infectivity. Because the assay measures biological activity rather than total particles, it can reveal effects that a particle count alone would not capture.

In neutralization testing, antibodies or other immune factors are assessed by whether they alter the measured infectivity of a sample. The assay can therefore connect an immune intervention with a change in infectious units, rather than only with a change in particle abundance. This makes it useful for examining how host defenses influence infection under the selected cell-culture conditions.